Durante, M., Ye, J. C., Hillengass, J., Sborov, D., Hoffman, J., Diamond, B., Coffey, D., Kaddoura, M., Pandey, A., Koubek, K., Mompoint, S., Gutierrez, S., Diaz, C., Armogan, M., Baz, R., Orlowski, R., Jandl, T., Korde, N., Simmons, H., Jacob, A., Shain, K., Kazandjian, D., Landgren, O. (2025). Disease burden by NGS in bone marrow and peripheral blood samples at baseline and after frontline therapy: Subgroup analysis of the advance randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM). Blood. https://doi.org/10.1182/blood-2025-7454